Executive Vice President and Chief Strategy Officer, AbbVie
Henry Gosebruch is Executive Vice President and Chief Strategy Officer at AbbVie, a global pharmaceutical company employing approximately 28,000 people and marketing medicines in more than 170 countries. As a member of AbbVie’s Executive Leadership Team, he is responsible for Corporate Strategic Planning, Licensing and Acquisitions, Alliance Management, Venture Capital Investments, and Early Stage Collaborations. Henry’s focus is to continue the advancement of AbbVie’s corporate strategy and to identify external opportunities to complement AbbVie’s internal innovation with partnered innovation in order to bring a consistent stream of innovative new medicines to patients worldwide.
Henry joined AbbVie in 2015. Prior to his AbbVie appointment, Henry was Co-Head of J.P. Morgan’s North American Mergers & Acquisitions Group based in New York. He was a member of J.P. Morgan’s M&A group for more than 20 years where he worked on announced M&A transactions in excess of $375 billion in total value involving companies in more than 20 countries. Henry is a frequent speaker on M&A panels and has been quoted by or appeared in articles by Bloomberg, CFO Magazine, the Financial Times and the New York Times. He has also been a faculty member of the Pli (Practising Law Institute) regarding M&A since 2010. In October 2007 he was selected by the New York Times for its Face Book of Wall Street’s Future listing 100 bankers, lawyers and investors.
Henry graduated from the Wharton School at the University of Pennsylvania in 1995. He is a member of the advisory board for the Life Sciences & Management Program at the University of Pennsylvania.